Vaccines to prevent pneumonia and improve child survival

Bulletin of the World Health Organization

Volumn 86, Issue 5, 2008, Pages 365-372

  Madhi, Shabir A ^a   Levine, Orin S ^b   Hajjeh, Rana ^b   Mansoor, Osman D ^c   Cherian, Thomas ^d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNITED NATIONS   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE;

CHILD HEALTH; COST-BENEFIT ANALYSIS; HEALTH SERVICES; IMMUNIZATION; LOW INCOME POPULATION; MORTALITY; PNEUMONIA; STRATEGIC APPROACH; SURVIVAL; VACCINE; WORLD HEALTH ORGANIZATION;

ARTICLE; CHILD; CHILDHOOD DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFLUENZA VACCINATION; MEASLES; PERTUSSIS; PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CHILD; FINANCING, ORGANIZED; HAEMOPHILUS VACCINES; HUMANS; INTERNATIONAL COOPERATION; MEASLES; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; SENTINEL SURVEILLANCE; WHOOPING COUGH; WORLD HEALTH;

AFRICA; SUB-SAHARAN AFRICA;

BACTERIA (MICROORGANISMS); HAEMOPHILUS INFLUENZAE SEROTYPE B; STREPTOCOCCUS PNEUMONIAE;

EID: 43749103581     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.07.044503     Document Type: Article

References (59)

1. Pneumonia: the forgotten killer of children. Geneva: UNICEF/WHO; 2006.
2. Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? Lancet 2003;361:2226-34.
3. Sazawal S, Black RE. Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials. Lancet Infect Dis 2003;3:547-56.
4. Vaccine preventable deaths and the global immunization vision and strategy, 2006-2015. MMWR Morb Mortal Wkly Rep 2006;55:511-5.
5. Pertussis vaccines - WHO position paper. Wkly Epidemiol Rec 2005;80:31-9.
6. Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect Dis 2003;3:413-8.
7. Duke T, Mgone CS. Measles: not just another viral exanthem. Lancet 2003; 361:763-73.
8. Morton R, Mee J. Measles pneumonia: lung puncture findings in 56 cases related to chest X-ray changes and clinical features. Ann Trop Paediatr 1986; 6:41-5.
9. Quiambao BP, Gatchalian SR, Halonen P, Lucero M, Sombrero L, Paladin FJ, et al. Co-infection is common in measles-associated pneumonia. Pediatr Infect Dis J 1998;17:89-93.
10. Progress in reducing global measles deaths, 1999-2004. MMWR Morb Mortal Wkly Rep 2006;55:247-9.
11. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 2007;369:191-200.
12. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine. Lancet 1997;349:1191-7.
13. Levine OS, Lagos R, Munoz A, Villaroel J, Alvarez AM, Abrego P, et al. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 1999;18:1060-4.
14. Gessner BD, Sutanto A, Linehan M, Djelantik IG, Fletcher T, Gerudug IK, et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 2005;365:43-52.
15. Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006;25:779-81.
16. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349:1341-8.
17. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005;365:1139-46.
18. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003;362:355-61.
19. de Andrade AL, de Andrade JG, Martelli CM, e Silva SA, de Oliveira RM, Costa MS, et al. Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil. Int J Epidemiol 2004;33:173-81.
20. de la Hoz F, Higuera AB, Di Fabio JL, Luna M, Naranjo AG, de la Luz Valencia M, et al. Effectiveness of Haemophilus influenzae type b vaccination against bacterial pneumonia in Colombia. Vaccine 2004;23:36-42.
21. Baqui AH, El Arifeen S, Saha SK, Persson L, Zaman K, Gessner BD, et al. Effectiveness of Haemophilus influenzae type b conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study. Pediatr Infect Dis J 2007;26:565-71.
22. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. 22. Wkly Epidemiol Rec 2007;82:93-104.
23. Cherian T, Mulholland EK, Carlin JB, Ostensen H, Amin R, de Campo M, et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ 2005;83:353-9.
24. Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005;40:1511-8.
25. Madhi SA, Klugman KP. World Health Organisation definition of "radiologically-confirmed pneumonia" may under-estimate the true public health value of conjugate pneumococcal vaccines. Vaccine 2007;25:2413-9.
26. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007;369:1179-86.
27. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004;113:701-7.
28. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004;10:811-3.
29. Klugman KP, Madhi SA. Pneumococcal vaccines and flu preparedness. Science 2007;316:49-50.
30. Klugman KP. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infect Dis 2001;1:85-91.
31. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46.
32. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54:893-7.
33. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007;297:1784-92.
34. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-9.
35. WHO position paper on Haemophilus influenzae type b conjugate vaccines (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record). Wkly Epidemiol Rec 2006;81:445-52.
36. Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 2007;120:e553-64.
37. Smith S, Demicheli V, Di Pietrantonj C, Harnden AR, Jefferson T, Matheson NJ, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2006;1:CD004879.
38. Manzoli L, Schioppa F, Boccia A, Villari P. The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr Infect Dis J 2007; 26:97-106.
39. Allison MA, Daley MF, Crane LA, Barrow J, Beaty BL, Allred N, et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season. J Pediatr 2006;149:755-62.
40. Graham SM, Gibb DM. HIV disease and respiratory infection in children. Br Med Bull 2002;61:133-50.
41. Zwi KJ, Pettifor JM, Soderlund N. Paediatric hospital admissions at a South African urban regional hospital: the impact of HIV, 1992-1997. Ann Trop Paediatr 1999;19:135-42.
42. Gibb D, Spoülou V, Giacomelli A, Griffiths H, Masters J, Misbah S, et al. Antibody responses to Haemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1995;14:129-35.
43. Madhi SA, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005;24:410-6.
44. Gibb D, Giacomelli A, Masters J, Spoulou V, Ruga E, Griffiths H, et al. Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. Pediatr Infect Dis J 1996;15:1097-101.
45. Madhi SA, Kuwanda L, Saarinen L, Cutland C, Mothupi R, Käyhty H, et al. Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 2005;23:5517-25.
46. Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis 2004;4:510-8.
47. Abzug MJ, Pelton SI, Song LY, Fenton T, Levin MJ, Nachman SA, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006;25:920-9.
48. Madhi SA, Petersen K, Khoosal M, Huebner RE, Mbelle N, Mothupi R, et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002;21:315-21.
49. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367:740-8.
50. Shann F. Haemophilus influenzae pneumonia: type b or non-type b? Lancet 1999;354:1488-90.
51. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr, Boyce TG, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000;182:1331-42.
52. Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med 2002;96 Suppl B;S1-7.
53. Simoes EA. Respiratory syncytial virus infection. Lancet 1999;354:847-52.
54. Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 2004; 189:462-70.
55. Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. Increased disease burden and antibiotic resistance of bacteria causing severe community acquired lower respiratory tract infections in human immunodeficiency 27 virus type 1-infected children. Clin Infect Dis 2000;31:170-6.
56. Zar HJ, Hanslo D, Tannenbaum E, Klein M, Argent A, Eley B, et al. Aetiology and outcome of pneumonia in human immunodeficiency virus-infected children hospitalized in South Africa. Acta Paediatr 2001;90:119-25.
57. Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet 2006;367:1193-208.
58. Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007;369:389-96.
59. Miller MA, McCann L. Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ 2000;9:19-35.